These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18853832)

  • 21. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of heparin on three whole blood activated clotting tests and thrombin time.
    Uden DL; Seay RE; Kriesmer PJ; Cipolle RJ; Payne NR
    ASAIO Trans; 1991; 37(2):88-91. PubMed ID: 1854557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
    Kim YS; Murkin JM; Adams SJ
    Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery.
    Yamamoto T; Wolf HG; Sinzobahamvya N; Asfour B; Hraska V; Schindler E
    Thorac Cardiovasc Surg; 2015 Aug; 63(5):397-403. PubMed ID: 26121380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi.
    Hellstern P; Bach J; Simon M; Saggau W
    J Extra Corpor Technol; 2007 Jun; 39(2):81-6. PubMed ID: 17672188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interchangeability of activated clotting time values across different point-of-care systems.
    Thenappan T; Swamy R; Shah A; Nathan S; Nichols J; Bond L; Jolly N
    Am J Cardiol; 2012 May; 109(9):1379-82. PubMed ID: 22341924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Percutaneous transluminal coronary angioplasty: comparison of arterial vs. venous activated clotting time.
    Pesola GR; Johnson A; Pesola DA
    Cathet Cardiovasc Diagn; 1996 Feb; 37(2):140-4. PubMed ID: 8808068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation of the i-STAT kaolin activated clotting time (ACT) test in different clinical settings in a large academic urban medical center: comparison with the Medtronic ACT Plus.
    Lewandrowski EL; Van Cott EM; Gregory K; Jang IK; Lewandrowski KB
    Am J Clin Pathol; 2011 May; 135(5):741-8. PubMed ID: 21502428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Point-of-care testing of activated clotting time in the ICU: is it relevant?
    Brown E; Clarke J; Edward KL; Giandinoto JA
    Br J Nurs; 2016 Jun 9-22; 25(11):608-12. PubMed ID: 27281594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The in vitro effects of aprotinin on twelve different ACT tests.
    Jones K; Nasrallah F; Darling E; Clay N; Searles B
    J Extra Corpor Technol; 2004 Mar; 36(1):51-7. PubMed ID: 15095841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison between arterial- and venous-sampled activated clotting time measurements.
    Zisman E; Rozenberg B; Katz Y; Ziser A
    Isr J Med Sci; 1997 Dec; 33(12):786-8. PubMed ID: 9464347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of anticoagulation using activated clotting times in patients receiving intravenous enoxaparin during percutaneous coronary intervention.
    Lawrence M; Mixon TA; Cross D; Gantt DS; Dehmer GJ
    Catheter Cardiovasc Interv; 2004 Jan; 61(1):52-5. PubMed ID: 14696159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory.
    Doherty TM; Shavelle RM; French WJ
    Catheter Cardiovasc Interv; 2005 Jul; 65(3):330-7. PubMed ID: 15864806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses.
    Despotis GJ; Alsoufiev AL; Spitznagel E; Goodnough LT; Lappas DG
    Ann Thorac Surg; 1996 Mar; 61(3):795-9. PubMed ID: 8619695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
    J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of heparin-coated pulmonary artery catheters on activated coagulation time in cardiac surgical patients.
    Haering JM; Maslow AD; Parker RA; Lowenstein E; Comunale ME
    J Cardiothorac Vasc Anesth; 2000 Jun; 14(3):260-3. PubMed ID: 10890477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Guidelines for certification of Activated clotting time (ACT) according to the EN ISO 22870 standards].
    Lasne D; Bauters A; Le Querrec A; Bourdin C; Voisin S; ;
    Ann Biol Clin (Paris); 2015; 73(2):225-54. PubMed ID: 25847747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Viscoelastic blood coagulation measurement with Sonoclot predicts postoperative bleeding in cardiac surgery after heparin reversal.
    Bischof DB; Ganter MT; Shore-Lesserson L; Hartnack S; Klaghofer R; Graves K; Genoni M; Hofer CK
    J Cardiothorac Vasc Anesth; 2015; 29(3):715-22. PubMed ID: 25864405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
    Cavusoglu E; Lakhani M; Marmur JD
    J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation.
    Chia S; Van Cott EM; Raffel OC; Jang IK
    Thromb Haemost; 2009 Mar; 101(3):535-40. PubMed ID: 19277416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.